{"id":1063122,"date":"2011-12-04T16:57:56","date_gmt":"2011-12-04T16:57:56","guid":{"rendered":"http:\/\/www.longevitymedicine.tv\/researcher-alert-cirm-readying-57-million-in-new-opportunities\/"},"modified":"2024-08-17T20:27:13","modified_gmt":"2024-08-18T00:27:13","slug":"researcher-alert-cirm-readying-57-million-in-new-opportunities-2","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/stem-cell-therapy\/researcher-alert-cirm-readying-57-million-in-new-opportunities-2.php","title":{"rendered":"Researcher Alert: CIRM Readying $57 Million in New Opportunities"},"content":{"rendered":"

<\/a>
<\/a><\/p>

The California stem cell agency is proposing to pump $30 million into new research involving reprogrammed adult stem cells and another $27 million into fresh efforts to speed development of clinical therapies. <\/p>

In a memo<\/a> prepared for the CIRM<\/b> directors meeting next week in Los Angeles<\/a>, the agency's staff said the $30 million effort could generate \"disease-in-a-dish models\" that \"have the potential to make drug discovery faster, more efficient and more personalized to individual patients.\"<\/p>

The \"disease-in-a-dish\" plan was dubbed a \"human pluripotent stem cell (hPSC) initiative\" by the staff. The goal is to generate high quality stem cell-based tools for use by the researchers and drug developers. <\/p>

The proposal includes four elements, one of which is collaboration with the NIH<\/b> to develop cell lines from patients with Huntington’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis. No cost was specified on that effort. Also recommended to directors was a $4 million disease line award round, a $16 million core hiPSC derivation round and a $10 million stem cell bank round. The RFAs would go out in May of next year with funding expected early in 2013.<\/p>

The staff memo on the initiative did not mention human embryonic stem cells, but a spokeswoman for the agency said they were not excluded from the effort.<\/p>

The other new grant proposals up next week grew out of a recommendations from a blue-ribbon panel that CIRM organized last year to examine its operations. One element in the plan is a $12 million \"bridging fund\"<\/a> that would apply only to current CIRM-funded projects in three areas: disease team grants, some early translational projects and clinical development projects. The bridging fund would provide up to $3 million for up to one year for each recipient, if CIRM President Alan Trounson<\/b> approves the project. Trounson would be assisted in his evaluation by staff and external consultants, if necessary. <\/p>

The second part of the response to the review panel's finding is an \"external innovation initiative\" <\/a>to support collaborative efforts of CIRM grantees to work with teams that CIRM said are \"making extraordinary progress outside California.\"<\/p>

The $15 million program would provide awards as often as two times a year. The maximum amount on each award was not specified. <\/p>

Ellen Feigal<\/b>, CIRM's vice president of research and development, said in a memo to directors that examples of potential projects included collaborative efforts with the NIH and work with the Harvard Stem Cell Institute<\/b> and its disease-focused programs. <\/p>

Some of the latest CIRM initiatives are open to biotech businesses. Others are open only to non-profit or academic researchers.<\/p>

(Editor's note: An earlier version of this item did not include the sentence dealing with human embryonic stem cells.)<\/p>

\"\"<\/div>

Source:
http:\/\/californiastemcellreport.blogspot.com\/feeds\/posts\/default?alt=rss<\/a><\/p>","protected":false},"excerpt":{"rendered":"

The California stem cell agency is proposing to pump $30 million into new research involving reprogrammed adult stem cells and another $27 million into fresh efforts to speed development of clinical therapies. In a memo prepared for the CIRM directors … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[25,1246878],"tags":[],"class_list":["post-1063122","post","type-post","status-publish","format-standard","hentry","category-stem-cell-therapy","category-stem-cells"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1063122"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1063122"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1063122\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1063122"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1063122"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1063122"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}